9X1 Stock Overview Develops, produces, and markets pharmaceutical solutions worldwide. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Procaps Group S.A. Competitors Price History & Performance
Summary of share price highs, lows and changes for Procaps Group Historical stock prices Current Share Price US$1.98 52 Week High US$3.70 52 Week Low US$1.04 Beta 0.10 1 Month Change 57.14% 3 Month Change 41.43% 1 Year Change -16.81% 3 Year Change -74.29% 5 Year Change n/a Change since IPO -79.16%
Recent News & Updates
Procaps Group S.A., Annual General Meeting, Dec 16, 2024 Dec 02
Procaps Group, S.A. Announces Resignation of Board Members Nov 29
Procaps Receives Nasdaq Listing Determination, to Request Hearing and Further Stay Pending Hearing Nov 19
New minor risk - Market cap size Nov 14
High number of new directors Nov 12
Investor sentiment deteriorates as stock falls 20% Nov 08 See more updates
Procaps Group S.A., Annual General Meeting, Dec 16, 2024 Dec 02
Procaps Group, S.A. Announces Resignation of Board Members Nov 29
Procaps Receives Nasdaq Listing Determination, to Request Hearing and Further Stay Pending Hearing Nov 19
New minor risk - Market cap size Nov 14
High number of new directors Nov 12
Investor sentiment deteriorates as stock falls 20% Nov 08
Investor sentiment improves as stock rises 19% Oct 12
Procaps Group S.A. Announces Resignation of Ruben Minski as Board of Directors Oct 09
Investor sentiment deteriorates as stock falls 17% Sep 06
Hoche Partners Raises Concerns on Shareholder Letter Issued by Procaps Group Sep 05
High number of new directors Aug 01
Hoche Partners Criticizes Procaps Group's Majority Shareholder for Mismanagement and Rejection of Financial Restructuring Offer Jul 30
Procaps Group S.A. Announces Board Changes Jun 28 Procaps Group S.A. announced delayed 20-F filing May 03
Procaps Group S.A. Provides Earnings Guidance for the Year Ended December 31, 2023 May 02
Investor sentiment deteriorates as stock falls 17% Apr 03
Investor sentiment improves as stock rises 21% Mar 12
Procaps Group S.A. Announces Formation of Strategic Committee to Explore Value Creation Alternatives Mar 05
Investor sentiment deteriorates as stock falls 23% Feb 14
New major risk - Revenue and earnings growth Jan 16
Hoche Partners Sends a Letter to Procaps Group Jan 14
Hoche Partners Sends a Letter to Procaps Group Jan 13
Investor sentiment improves as stock rises 24% Jan 02
Third quarter 2023 earnings released: EPS: US$0.08 (vs US$0.22 in 3Q 2022) Dec 27
Investor sentiment improves as stock rises 26% Nov 25
Procaps Group S.A. Announces Executive Changes, Effective January 15, 2024 Nov 24
Procaps Group S.A. Announces Executive Changes, Effective January 15, 2024 Nov 23
Procaps Group S.A. to Report Q3, 2023 Results on Nov 14, 2023 Nov 11
Investor sentiment deteriorates as stock falls 17% Nov 10
Investor sentiment improves as stock rises 23% Oct 26
Procaps Group S.A. Appoints Sandra Sanchez Y Oldenhage as A Director Oct 25
Investor sentiment deteriorates as stock falls 20% Oct 10
Second quarter 2023 earnings released: EPS: US$0.27 (vs US$0.068 loss in 2Q 2022) Sep 07
New major risk - Earnings quality Sep 06
Procaps Group S.A. to Report Q2, 2023 Results on Sep 05, 2023 Sep 01
Procaps Group S.A., Annual General Meeting, Jun 30, 2023 Jun 15
Procaps Group S.A. to Report Q1, 2023 Results on Jun 05, 2023 Jun 06
Full year 2022 earnings released: EPS: US$0.42 (vs US$1.03 loss in FY 2021) May 14
Investor sentiment improves as stock rises 17% Apr 26
Investor sentiment improves as stock rises 25% Mar 28
Now 22% undervalued after recent price drop Mar 03
Investor sentiment improves as stock rises 15% Feb 28
Less than half of directors are independent Feb 18 Procaps Group S.A. Announces Board Changes Procaps Group S.A. (NasdaqGM:PROC) announces an Equity Buyback for 2,000,000 shares, for $5 million.
Investor sentiment deteriorates as stock falls 19% Feb 11
Now 23% undervalued after recent price drop Feb 09
Procaps Group Announces Key Changes to the Board of Directors Jan 20
Investor sentiment deteriorated over the past week Dec 26
Third quarter 2022 earnings released: EPS: US$0.22 (vs US$1.14 loss in 3Q 2021) Nov 16
Procaps Group S.A. to Report Q3, 2022 Results on Nov 14, 2022 Nov 09
Second quarter 2022 earnings released: US$0.07 loss per share (vs US$0.01 loss in 2Q 2021) Aug 31
Now 20% undervalued after recent price drop Aug 17
Procaps Group S.A., Annual General Meeting, Jun 28, 2022 Jun 02
Procaps Group S.A. (NasdaqGM:PROC) entered into an agreenment to acquire Grupo Farmacéutico Somar, Sociedad Anónima Promotora de Inversión de Capital Variable from Advent International Corporation. May 19
Procaps Group S.A. (NasdaqGM:PROC) entered into an agreenment to acquire Grupo Farmacéutico Somar, Sociedad Anónima Promotora de Inversión de Capital Variable from Advent International Corporation. May 18
Full year 2021 earnings released: US$1.03 loss per share (vs US$5.22 loss in FY 2020) May 03
Forecast to breakeven in 2022 Apr 27
Now 21% undervalued after recent price drop Apr 19
Procaps Group Announces Appointment of Melissa Angelini as Investor Relations Director Jan 30
Procaps Group, S.A. (NasdaqGM:PROC) acquired 86,000 sq. ft. Pharmaceutical Production Facility Located in West Palm Beach, Florida from Strides Pharma Inc. Jan 13
Less than half of directors are independent Oct 29 Shareholder Returns 9X1 DE Pharmaceuticals DE Market 7D -0.5% -3.4% -1.1% 1Y -16.8% -14.4% 8.1%
See full shareholder returns
Return vs Market: 9X1 underperformed the German Market which returned 9.2% over the past year.
Price Volatility Is 9X1's price volatile compared to industry and market? 9X1 volatility 9X1 Average Weekly Movement 31.6% Pharmaceuticals Industry Average Movement 5.6% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.8% 10% least volatile stocks in DE Market 2.5%
Stable Share Price: 9X1's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 9X1's weekly volatility has increased from 16% to 32% over the past year.
About the Company Procaps Group S.A. develops, produces, and markets pharmaceutical solutions worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory. It also provides drugs for hospital use, such as antibiotic, blood clot, personal protective equipment, immunosuppressant, oncology, and analgesics products.
Show more Procaps Group S.A. Fundamentals Summary How do Procaps Group's earnings and revenue compare to its market cap? 9X1 fundamental statistics Market cap €396.96m Earnings (TTM ) €49.78m Revenue (TTM ) €394.84m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 9X1 income statement (TTM ) Revenue US$414.10m Cost of Revenue US$186.19m Gross Profit US$227.91m Other Expenses US$175.71m Earnings US$52.20m
Last Reported Earnings
Sep 30, 2023
Earnings per share (EPS) 0.46 Gross Margin 55.04% Net Profit Margin 12.61% Debt/Equity Ratio 663.2%
How did 9X1 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/18 03:22 End of Day Share Price 2024/12/16 00:00 Earnings 2023/09/30 Annual Earnings 2022/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Procaps Group S.A. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Brian Kemp Dolliver Brookline Capital Markets Samuel Campos Alves BTG Pactual
Show 0 more analysts 